2024
Five-year evaluation of Anal Cancer Screening Program in Men Who Have Sex With Men with HIV at Two Academic Center Clinics
Achhra A, Chan E, Applebaum S, Guerrero M, Hao R, Pantel H, Virata M, Fikrig M, Barakat L. Five-year evaluation of Anal Cancer Screening Program in Men Who Have Sex With Men with HIV at Two Academic Center Clinics. Clinical Infectious Diseases 2024, ciae541. PMID: 39492696, DOI: 10.1093/cid/ciae541.Peer-Reviewed Original ResearchHigh-resolution anoscopyAnal cytologyAnal cancer screening programAbnormal anal cytologyAcademic HIV clinicSquamous cell carcinomaRetrospective chart reviewHistory of smokingEligible populationCancer screening programDetecting HSILAbnormal cytologyTriage testCell carcinomaHIV clinicChart reviewOlder age groupsHSILFollow-upCytologyScreening programScreening testCenter clinicIncreasing ageEligible individualsThe Feasibility and Acceptability of a Clinical Pharmacist-delivered Intervention to Reduce Bothersome Health Symptoms from Polypharmacy and Alcohol Use and Communicate Risk among People with HIV: Pilot Study Protocol
Womack J, Leblanc M, Sager A, Zaets L, Maisto S, Garcia A, Aoun-Barakat L, Brown S, Edelman E, Fiellin D, Fisher J, Fraenkel L, Kidwai-Khan F, Marconi V, Martino S, Pulk R, Satre D, Virata M, Justice A, Hsieh E. The Feasibility and Acceptability of a Clinical Pharmacist-delivered Intervention to Reduce Bothersome Health Symptoms from Polypharmacy and Alcohol Use and Communicate Risk among People with HIV: Pilot Study Protocol. AIDS And Behavior 2024, 1-15. PMID: 39465468, DOI: 10.1007/s10461-024-04533-6.Peer-Reviewed Original ResearchUnhealthy alcohol useAlcohol usePharmacist-delivered interventionVeterans Aging Cohort StudyPilot study protocolStudy protocolElectronic health recordsSupport behavior changePre-test/post-test designAging Cohort StudySelf-administered surveyAlcohol use disorderAlcohol Research CenterBothersome symptomsPre-test/post-testCommunicating riskHealth recordsLong-term medicationHealth symptomsCounseling interventionCounseling sessionsSessions 2 weeksQualitative interviewsAlcohol consumptionUse disorder
2023
Perspectives on unhealthy alcohol use among men who have sex with men prescribed HIV pre-exposure prophylaxis: A qualitative study
Strong S, Oldfield B, van den Berg J, Cole C, Biegacki E, Ogbuagu O, Virata M, Chan P, Edelman E. Perspectives on unhealthy alcohol use among men who have sex with men prescribed HIV pre-exposure prophylaxis: A qualitative study. Preventive Medicine Reports 2023, 37: 102553. PMID: 38282665, PMCID: PMC10810836, DOI: 10.1016/j.pmedr.2023.102553.Peer-Reviewed Original ResearchUnhealthy alcohol usePre-exposure prophylaxisAlcohol reduction interventionsAlcohol useHIV pre-exposure prophylaxisOral pre-exposure prophylaxisAcquisition of HIVAlcohol-related harmPrEP adherencePrEP careTreatment optionsOral formulationReduction interventionsPrEP programMSMPrEPProphylaxisHIVMultimodal approachMenCareAdherenceInterventionSexUnited States1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022
Achhra A, Chan E, Applebaum S, Guerrero M, Hao R, Pantel H, Virata M, Barakat L. 1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022. Open Forum Infectious Diseases 2023, 10: ofad500.1314. PMCID: PMC10677807, DOI: 10.1093/ofid/ofad500.1314.Peer-Reviewed Original ResearchAnal dysplasiaAbnormal PapHIV clinicAnal cancer screening programsAmbulatory HIV clinicRetrospective chart reviewHistory of smokingCancer screening programsSquamous cell carcinomaAnal cytologyAntiretroviral therapyHIV careChart reviewClinic visitsMedian ageMultivariable analysisCell carcinomaScreening programPrior historyAge 35High riskType of insuranceBackground treatmentCharacteristics of peoplePWH1538. Is there value in performing yearly screening for latent tuberculosis infection by interferon-gamma release assay among patients living with HIV in non-endemic settings?
Palacios C, Achhra A, Barakat L, Virata M, Hao R, Baxter J, Malinis M. 1538. Is there value in performing yearly screening for latent tuberculosis infection by interferon-gamma release assay among patients living with HIV in non-endemic settings? Open Forum Infectious Diseases 2023, 10: ofad500.1373. PMCID: PMC10678242, DOI: 10.1093/ofid/ofad500.1373.Peer-Reviewed Original ResearchInterferon-gamma release assaysLatent tuberculosis infectionNew latent tuberculosis infectionsTuberculin skin testingNon-endemic settingRisk factorsCD4 countTuberculosis infectionCurrent guidelinesGroup APositive interferon-gamma release assaysHigher HIV viral loadUrban academic medical centerChest imaging resultsLow CD4 countTB exposure riskTB risk factorsCells/mm3HIV viral loadRetrospective chart reviewFeatures of patientsRisk of reactivationInterferon-gamma releaseCommon risk factorsAcademic medical centerBuilding an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections
Gleeson S, Zapata H, Bathgate M, Emu B, Frederick J, Friedland G, Golden M, Meyer J, Radin J, Sideleau R, Shaw A, Shenoi S, Trubin P, Virata M, Barakat L, Desruisseaux M. Building an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections. Clinical Infectious Diseases 2023, 77: 703-710. PMID: 37078888, DOI: 10.1093/cid/ciad236.Peer-Reviewed Original ResearchConceptsEducational activitiesHealthcare inequitiesInfectious Diseases SectionSingle-center experienceCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicMixed-methods assessmentLearning objectivesPilot curriculumEducational trainingCurriculumCenter experienceLong-term behavioral changesProgram outcomesDisease sectionDisease diversityPhysician perspectivesResponse rateHealth disparitiesYale SchoolInequitiesAntiracismBehavioral changesRacismEquityAvailability and Accessibility of Live Nonreplicating Smallpox/Mpox Vaccine
Kahn P, Ying X, Virata M, Magahis P, Li S, Mathis W. Availability and Accessibility of Live Nonreplicating Smallpox/Mpox Vaccine. JAMA Network Open 2023, 6: e237873. PMID: 37027158, PMCID: PMC10082399, DOI: 10.1001/jamanetworkopen.2023.7873.Peer-Reviewed Original Research
2021
843. Targeted HIV Testing for Patients Hospitalized for COVID-19
Virata M, Villanueva M, Miceli J. 843. Targeted HIV Testing for Patients Hospitalized for COVID-19. Open Forum Infectious Diseases 2021, 8: 512-512. PMCID: PMC8643876, DOI: 10.1093/ofid/ofab466.1038.Peer-Reviewed Original ResearchYale New Haven Health SystemHIV risk factorsCOVID-19 infectionHIV testingSARS-CoV-2Comorbidity scoreRisk factorsProtease inhibitorsUse of PIsAppropriate HIV treatmentComorbidity of HIVHIV testing resultsMajority of PWHPerformance of HIVTargeted HIV TestingElixhauser comorbidity scoreSubset of patientsLimited clinical dataSevere respiratory illnessHIV infection ratesSpecific underlying conditionLarge healthcare systemCOVID-19Chi-squared analysisComplicated diabetes
2020
543. SARS-CoV-2 Viral Dynamics For Symptomatic People Living with HIV Requiring Hospitalization For COVID-19
Virata M, Villanueva M, Shenoi S, Ladines-Lim J, Aoun-Barakat L. 543. SARS-CoV-2 Viral Dynamics For Symptomatic People Living with HIV Requiring Hospitalization For COVID-19. Open Forum Infectious Diseases 2020, 7: s338-s338. PMCID: PMC7777445, DOI: 10.1093/ofid/ofaa439.737.Peer-Reviewed Original ResearchSARS-CoV-2 viral loadViral loadRespiratory samplesViral dynamicsUndetectable HIV viral loadSARS-CoV-2 infectionSevere acute respiratory syndrome 2SARS-CoV-2 viral dynamicsMedian CD4 countRetrospective cohort studyCells/mm3HIV viral loadRNA viral loadMain outcome measuresUrban academic centerCT of patientsPresentation of illnessYears of ageCOVID-19SARS-CoV-2COVID-19 diseaseCycle threshold valuesHospital mortalityAdvanced diseaseCD4 count
2018
566. Earlier Linkage and ART Initiation Via Fast Track Referral System for New HIV Patients Leads to Stronger Engagement and Better Outcomes
Virata M, Comia C, Cudahy P. 566. Earlier Linkage and ART Initiation Via Fast Track Referral System for New HIV Patients Leads to Stronger Engagement and Better Outcomes. Open Forum Infectious Diseases 2018, 5: s210-s210. PMCID: PMC6255605, DOI: 10.1093/ofid/ofy210.574.Peer-Reviewed Original ResearchEarly intervention servicesAntiretroviral therapyViral suppressionStandard of careCD4 recoveryHIV careFast-track referral systemNew HIV patientsDays of diagnosisSingle academic centerLocal health departmentsPublic health perspectiveART initiationHIV patientsOnly patientsInitial visitMedical recordsAcademic clinicEarly initiationNew patientsOutcome dataReferral systemBetter OutcomesPatientsAcademic centers
2017
Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva M, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017, 6: 620. DOI: 10.12688/f1000research.11397.1.Peer-Reviewed Original ResearchHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infection
2014
673Comparative Effectiveness of Vancomycin vs Early Daptomycin for MRSA Bacteremia with Vancomycin MIC >1 mg/L: A Multicenter Evaluation
Moise P, Culshaw D, Wong-Beringer A, Bensman J, Lamp K, Smith W, Bauer K, Goff D, Adamson R, Leuthner K, Virata M, Mckinnell J, Chaudhry S, Eskandarian R, Lodise T, Reyes K, Zervos M. 673Comparative Effectiveness of Vancomycin vs Early Daptomycin for MRSA Bacteremia with Vancomycin MIC >1 mg/L: A Multicenter Evaluation. Open Forum Infectious Diseases 2014, 1: s190-s190. PMCID: PMC5781468, DOI: 10.1093/ofid/ofu052.381.Peer-Reviewed Original ResearchPT271 Prevalence of Metabolic Syndrome in Patients with HIV in the Era of Highly Active Antiretroviral Therapy
Lombo B, Fotjadhi I, Ravi S, Golden M, Virata M, Lievano M, Diez J, Ghantous A, Donohue T. PT271 Prevalence of Metabolic Syndrome in Patients with HIV in the Era of Highly Active Antiretroviral Therapy. Global Heart 2014, 9: e219. DOI: 10.1016/j.gheart.2014.03.2016.Peer-Reviewed Original Research
1996
Invasive Pneumococcal Disease: Clinical Features, Serotypes, and Antimicrobial Resistance Patterns in Cases Involving Patients with and Without Human Immunodeficiency Virus Infection
Frankel R, Virata M, Hardalo C, Altice F, Friedland G. Invasive Pneumococcal Disease: Clinical Features, Serotypes, and Antimicrobial Resistance Patterns in Cases Involving Patients with and Without Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 1996, 23: 577-584. PMID: 8879783, DOI: 10.1093/clinids/23.3.577.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal diseaseClinical featuresPenicillin-resistant pneumococcal infectionsHuman immunodeficiency virus (HIV) diseaseHuman immunodeficiency virus (HIV) infectionCommon capsular typesSource of bacteremiaImmunodeficiency virus infectionOverall mortality rateAntibiotic susceptibility patternPolyvalent pneumococcal vaccineType 9VCommon risk factorsPenicillin-resistant isolatesAntimicrobial resistance patternsPneumococcal infectionPneumococcal vaccineHIV infectionHIV serostatusHIV statusRecurrence rateInvasive diseaseRisk factorsSusceptibility patterns